A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Cancer Stage IV|HER2-negative Breast Cancer|Solid Carcinoma|MEK1 Gene Mutation|MEK2 Gene Mutation|Metastatic Breast Cancer
Interventions: DRUG: Mirdametinib|DRUG: Fulvestrant
Sponsor: Memorial Sloan Kettering Cancer Center